Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Panbela Therapeutics ( (PBLA) ) has shared an announcement.
On January 29, 2025, Panbela Therapeutics’ Compensation Committee approved retention arrangements for its employees, including CEO Jennifer K. Simpson and CFO Susan Horvath, to ensure their continued employment. These arrangements offer cash retention bonuses contingent on certain conditions such as achieving a significant cash balance or a change in control, potentially impacting the company’s financial strategy and stability.
More about Panbela Therapeutics
Panbela Therapeutics, Inc. operates in the pharmaceutical industry, focusing on the development of therapeutics.
YTD Price Performance: -22.22%
Average Trading Volume: 17,181
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $1.7M
Find detailed analytics on PBLA stock on TipRanks’ Stock Analysis page.